Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome

Luis Amselem, Javier Montero, Manuel Diaz-Llopis, Jose S Pulido, Sophie J. Bakri, Paula Palomares, Salvador Garcia-Delpech

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.

Original languageEnglish (US)
Pages (from-to)122-124
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume144
Issue number1
DOIs
StatePublished - Jul 2007

Fingerprint

Iris
Macular Edema
Injections
Intraocular Pressure
Visual Acuity
Eye Pain
Intravitreal Injections
Optical Coherence Tomography
Outcome Assessment (Health Care)
Bevacizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Amselem, L., Montero, J., Diaz-Llopis, M., Pulido, J. S., Bakri, S. J., Palomares, P., & Garcia-Delpech, S. (2007). Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome. American Journal of Ophthalmology, 144(1), 122-124. https://doi.org/10.1016/j.ajo.2007.02.037

Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome. / Amselem, Luis; Montero, Javier; Diaz-Llopis, Manuel; Pulido, Jose S; Bakri, Sophie J.; Palomares, Paula; Garcia-Delpech, Salvador.

In: American Journal of Ophthalmology, Vol. 144, No. 1, 07.2007, p. 122-124.

Research output: Contribution to journalArticle

Amselem, L, Montero, J, Diaz-Llopis, M, Pulido, JS, Bakri, SJ, Palomares, P & Garcia-Delpech, S 2007, 'Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome', American Journal of Ophthalmology, vol. 144, no. 1, pp. 122-124. https://doi.org/10.1016/j.ajo.2007.02.037
Amselem, Luis ; Montero, Javier ; Diaz-Llopis, Manuel ; Pulido, Jose S ; Bakri, Sophie J. ; Palomares, Paula ; Garcia-Delpech, Salvador. / Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome. In: American Journal of Ophthalmology. 2007 ; Vol. 144, No. 1. pp. 122-124.
@article{66b2d0d5bff54d1ca2709cf4a324319e,
title = "Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome",
abstract = "Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.",
author = "Luis Amselem and Javier Montero and Manuel Diaz-Llopis and Pulido, {Jose S} and Bakri, {Sophie J.} and Paula Palomares and Salvador Garcia-Delpech",
year = "2007",
month = "7",
doi = "10.1016/j.ajo.2007.02.037",
language = "English (US)",
volume = "144",
pages = "122--124",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome

AU - Amselem, Luis

AU - Montero, Javier

AU - Diaz-Llopis, Manuel

AU - Pulido, Jose S

AU - Bakri, Sophie J.

AU - Palomares, Paula

AU - Garcia-Delpech, Salvador

PY - 2007/7

Y1 - 2007/7

N2 - Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.

AB - Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS). Design: Interventional case reports. Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications. Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present. Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.

UR - http://www.scopus.com/inward/record.url?scp=34250782794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250782794&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.02.037

DO - 10.1016/j.ajo.2007.02.037

M3 - Article

VL - 144

SP - 122

EP - 124

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -